P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000873248.60171.71 |
| _version_ | 1797287748537679872 |
|---|---|
| author | GALACTÉROS F. VOSKARIDOU E. HABIBI A. CANNAS G. JOSEPH L. LOKO G. DE MONTALEMBERT M. |
| author_facet | GALACTÉROS F. VOSKARIDOU E. HABIBI A. CANNAS G. JOSEPH L. LOKO G. DE MONTALEMBERT M. |
| author_sort | GALACTÉROS F. |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:38:03Z |
| format | Article |
| id | doaj.art-1aaf4d4318ed43fb8d006abed20f1b9e |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:38:03Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1aaf4d4318ed43fb8d006abed20f1b9e2024-03-02T04:32:17ZengWileyHemaSphere2572-92412022-08-016585810.1097/01.HS9.0000873248.60171.71202208004-00110P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?GALACTÉROS F.0VOSKARIDOU E.1HABIBI A.2CANNAS G.3JOSEPH L.4LOKO G.5DE MONTALEMBERT M.61 Unité des Maladies Génétiques du Globule Rouge, Henri-Mondor university hospital, Créteil, France, Créteil, FRANCE2 Thalassemia and Sickle Cell Disease Center, « Laiko » General Hospital, Athens, GREECE1 Unité des Maladies Génétiques du Globule Rouge, Henri-Mondor university hospital, Créteil, France, Créteil, FRANCE3 Edouard-Herriot hospital, Lyon, FRANCE4 Biotherapy department, Necker-Enfants Malades university hospital, Paris, FRANCE5 Martinique university hospital, Fort de France, FRANCE6 Pediatrics Department, Necker-Enfants Malades university hospital, Paris, FRANCEhttp://journals.lww.com/10.1097/01.HS9.0000873248.60171.71 |
| spellingShingle | GALACTÉROS F. VOSKARIDOU E. HABIBI A. CANNAS G. JOSEPH L. LOKO G. DE MONTALEMBERT M. P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? HemaSphere |
| title | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_full | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_fullStr | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_full_unstemmed | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_short | P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG? |
| title_sort | p 090 is a dedicated marketing approval of hydroxyurea in sickle cell disease may increase the clinical benefit of the drug |
| url | http://journals.lww.com/10.1097/01.HS9.0000873248.60171.71 |
| work_keys_str_mv | AT galacterosf p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT voskaridoue p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT habibia p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT cannasg p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT josephl p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT lokog p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug AT demontalembertm p090isadedicatedmarketingapprovalofhydroxyureainsicklecelldiseasemayincreasetheclinicalbenefitofthedrug |